Testing

The algorithm can be viewed here.

In May 2017, Mayo Medical Laboratories announced eight brand new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Clinical Laboratory News recently highlighted a Mayo Clinic study that shows how plasma ceramides may predict cardiovascular events in patients with or without coronary artery disease.

Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from a[...]

The algorithm can be viewed here.

European Heart Journal recently highlighted Mayo Clinic's new blood test that may predict cardiovascular events in patients with or without coronary artery disease.

The algorithm can be viewed here.

Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.

A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.

In February 2017, Mayo Medical Laboratories announced nine brand new tests along with numerous reference-value changes, obsolete tests, and algorithm changes.

Mayo Clinic has completed validation of its existing Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum test for the new biosimilar drug Inflectra. Clients[...]

In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.

The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.